- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02871609
Assessment of Longterm Ureteral Stenting
Longterm Ureteral Stenting: Assessment of Stent- Associated Morbidity, Associated Costs and Impact of Biofilms
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is performed to provide a better understanding of the influence of biofilms on ureteral stents on the entire spectrum of stent-associated morbidity in a longterm setting.
In addition, the trial is intended to give an overview of the incidence of complaints, the occurrence of complications and their economic aspects.
The influence of biofilms on the morbidity associated with longterm ureteral stenting is assessed.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
St. Gallen, Switzerland
- Urological Department, Cantonal Hospital of St. Gallen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with longterm indwelling ureteral stent (minimum of 2 months) undergoing regular changes
- Informed consent
- responsible patients
Exclusion Criteria:
- ongoing therapy: OAB, LUTS, urinary incontinence, chronic prostatitis, chronic pelvic pain syndrome
- insufficient language skills
- cognitive limitation
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with longterm ureteral stent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total biofilm mass on ureteral stents
Time Frame: Time of stent removal/change: three months (range 2-4 months) after last stent insertion/change
|
Time of stent removal/change: three months (range 2-4 months) after last stent insertion/change
|
Assessment of morbidity using the Ureteral Stent Symptom Questionnaire (USSQ)
Time Frame: Day of stent removal/change: three months (range 2-4 months) after last stent insertion/change
|
Day of stent removal/change: three months (range 2-4 months) after last stent insertion/change
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urine Culture
Time Frame: 2-6 months after stent insertion
|
2-6 months after stent insertion
|
|
Number of bacteria on stent surface, if applicable number of bacteria on two indwelling stents
Time Frame: 2-6 months after stent insertion
|
2-6 months after stent insertion
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 2-6 months after stent insertion
|
2-6 months after stent insertion
|
|
Assessment of costs arising from complications
Time Frame: 2-6 months after stent insertion
|
complications assessed by CTCAE v4.0
|
2-6 months after stent insertion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Patrick Betschart, Dr. med., Department of Urology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CTU 16.011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Longterm Indwelling Ureteral Stent
-
Mayo ClinicEnrolling by invitation
-
University of MinnesotaCompletedUreteral Stent DiscomfortUnited States
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityNot yet recruitingUreteral Stent-Related Symptom
-
Ambu Inc.Ambu A/SCompletedCystoscopy | Ureteral StentUnited States
-
Dr .S.B.PATANKARCompleted
-
Cantonal Hospital of St. GallenCompletedUreteral Stent Related MorbiditySwitzerland
-
Mansoura UniversityCompletedRelieve of Ureteral Stent SymptomsEgypt
-
Mansoura UniversityRecruitingUreteral Stent | Stent Related SymptomsEgypt
-
St. Petersburg State Pavlov Medical UniversityCompleted
-
En Chu Kong HospitalRecruitingHydronephrosis | Ureteral Stent Occlusion | Ureteral StenosisTaiwan
Clinical Trials on Stent examination, urinary analysis, USSQ questionnaire
-
Cantonal Hospital of St. GallenCompletedMorbidity | Ureteral Catheterization | BiofilmSwitzerland
-
Azienda Ospedaliera Città della Salute e della...CompletedPain | Ureteral Calculi | Symptoms and SignsItaly
-
National Cancer Institute (NCI)Active, not recruitingProstate CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)Active, not recruitingMetastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8United States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; Tata Memorial Hospital; Udaan TrustNot yet recruitingHIV InfectionUnited States, India
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Enrolling by invitationProstate CarcinomaUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)Not yet recruitingHIV Infection | Human Papillomavirus Infection | Human Papillomavirus-Related CarcinomaUnited States, India
-
MeLSyTech, LtdRecruitingPelvic Organ Prolapse | Female Urogenital DiseasesRussian Federation
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Solid Neoplasm | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)Recruiting